Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company.[1] Their lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy.
 | |
| Type | Public |
|---|---|
| Nasdaq: CATB Russell Microcap Index component | |
| Industry | Pharmaceuticals |
| Founded | 2008 |
| Headquarters | Cambridge, Massachusetts |
Key people | Jill C. Milne, Ph.D. (CEO)
Joanne M. Donovan, M.D., Ph.D. (Chief Medical Officer) Andrew Nichols, Ph.D. (Chief Scientific Officer), Deirdre A. Cunnane (Chief Legal Officer) |
| Products | Orally-delivered pharmaceuticals |
Number of employees | 24 (March 2019) |
In Catabasis’s Phase 2 MoveDMD clinical trial and open-label extension, edasalonexent was shown to preserve muscle function as assessed by the North Star Ambulatory Assessment and Timed Function Tests compared with the rate of change during an off-treatment control period. It also showed a significant decrease in CRP, muscle enzymes including CK, and decrease in heart rate to age-normative values.
References
- "Our Story - Our Company - Catabasis". www.catabasis.com. Retrieved 2017-02-17.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.